Utama › Kanser Paru-paru › Pennsylvania › Reading
Kajian klinikal Kanser Paru-paru di Reading, PA
11 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Reading (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Reading Hospital, West Reading · 1 mi jauh
- Ephrata Cancer Center, Ephrata · 17 mi jauh
- Sechler Family Cancer Center, Lebanon · 26 mi jauh
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Penn State Health Saint Joseph Medical Center, Reading
- Reading Hospital, West Reading · 1 mi jauh
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Mengambil pesertaFasa 3
- Reading Hospital, West Reading · 1 mi jauh
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Mengambil pesertaFasa 3
- Ephrata Cancer Center, Ephrata · 17 mi jauh
- Sechler Family Cancer Center, Lebanon · 26 mi jauh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- Reading Hospital, West Reading · 1 mi jauh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Reading Hospital - McGlinn Cancer Institute, West Reading · 1 mi jauh
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Reading Hospital, West Reading · 1 mi jauh
- Ephrata Cancer Center, Ephrata · 17 mi jauh
- Sechler Family Cancer Center, Lebanon · 26 mi jauh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Ephrata Cancer Center, Ephrata · 17 mi jauh
- Sechler Family Cancer Center, Lebanon · 26 mi jauh
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Ephrata Cancer Center, Ephrata · 17 mi jauh
- Sechler Family Cancer Center, Lebanon · 26 mi jauh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Ephrata Cancer Center, Ephrata · 17 mi jauh
- Sechler Family Cancer Center, Lebanon · 26 mi jauh
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Mengambil pesertaKajian pemerhatian
- US Digestive Health at Wyomissing, Wyomissing · 2 mi jauh
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di Reading
- Kanser Paru-paru Bukan Sel Kecil9 kajian
- Leukemia Mieloid Akut5 kajian
- Kanser Payudara5 kajian
- Gangguan Mengantuk Berlebihan5 kajian
- Kanser Prostat4 kajian
- Kanser (semua jenis)4 kajian
- Kanser Kolorektal3 kajian
- Narkolepsi3 kajian
- Gangguan Tidur3 kajian
- Keletihan3 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.